•:enago

 β -thalassemia intermedia (β -TI) is a term that describes is patients with a milder form of anemia than patients with-β-thalassemia major. Ineffective erythropoiesis, chronic hemolytic anemia, and iron overload are the main factors responsible for the disease process-prognosis in <u>patients with β -TI. Chronic anemia may have such</u> adverse effects, <u>such</u> as increased in gastrointestinal iron absorption and iron overload, which can turn can cause endocrine abnormalities, diabetes mellitus, osteoporosis, hypothyroidism, and hypogonadism. Iron chelation therapy, splenectomy, transfusion therapy, and modulation of fetal hemoglobin (HbF) production are several available the options available for managing patients with β -TI. Pharmacological agents that increase γ -globin production, like such as Hydroxyurea hydroxyurea (HU), as evidenced by an increased in HbF levels, have been considered as therapeutic agents for patients with β -thalassemiaTI. Increasing the synthesis of fetal hemoglobinHbF can help reduce anemia and, thereby, improve the clinical condition of patients with β-TI. In several patients with β-TI and in patients with sickle-cell disease, a riseIncreases in total HbF levels has have been repeatedly reported during HU treatment in several patients with β-TI and in patients with sickle-cell disease. HU treatment can reduce blood transfusion dependency and even make some patients transfusion free, increasing which in turn increases their energy state level and decreasing decreases splenomegaly. HU treatment It also is protective protects for against hypothyroidism, pulmonary hypertension, extramedullary hematopoiesis, leg ulcers, and osteoporosis. The <u>commonest most common</u> side effects of HU therapy treatment include neutropenia and thrombocytopenia, both of which these are predictable and easily manageable. In the few studies conducted on the side effects of HU treatment in β -TI patients with β -TI, dermatological, neurological, and gastrointestinal adverse effects were seen observed without any reports of endocrine abnormality, bone marrow suppression, or hematological toxicity. In the present study, we aimed to perform medium- to long-term follow-up of chronic low-dose HU treatment was

Comment [A1]: Once an abbreviation is introduced in the text, the abbreviated form is used consistently at all subsequent mentions.

Comment [A2]: In academic writing, it is preferable to use consistent terminology so that concepts are clearly understood. The term "HU therapy" has been revised to "HU treatment" for consistency.

Comment [A3]: Compound adjectives that modify a single noun are typically hyphenated, except when the first word of the adjective is an adverb ending with "-ly." Hyphens are used with these terms so that their meaning is understood clearly.

All material in this document is the intellectual property of Crimson Interactive Pvt. Ltd. The use of information and content in this document in whole or in part is forbidden unless express permission has been given in writing by Crimson Interactive Pvt. Ltd.

www.enago.com | www.enago.jp | www.enago.com.tr | www.enago.com.br | www.enago.de | www.enago.tw | www.enago.cn | www.enago.co.kr | www.enago.ru

•:enago

inspected in order to analyze the its effect of HU treatment on the thyroid function of patients with β -TI.

All material in this document is the intellectual property of Crimson Interactive Pvt. Ltd. The use of information and content in this document in whole or in part is forbidden unless express permission has been given in writing by Crimson Interactive Pvt. Ltd.

www.enago.com | www.enago.jp | www.enago.com.tr | www.enago.com.br | www.enago.de | www.enago.tw | www.enago.cn | www.enago.co.kr | www.enago.ru